King Pharmaceuticals, Wyeth amend Altace agreement
King Pharmaceuticals and Wyeth have amended and restated their co-promotion agreement for King's Altace (ramipril), an angiotensin converting enzyme (ACE) inhibitor to treat high blood pressure.
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.